tiprankstipranks
Trending News
More News >
Ovid Therapeutics Inc (OVID)
NASDAQ:OVID
Advertisement

Ovid Therapeutics (OVID) AI Stock Analysis

Compare
1,432 Followers

Top Page

OV

Ovid Therapeutics

(NASDAQ:OVID)

Rating:49Neutral
Price Target:
$0.50
▲(4.17%Upside)
The overall stock score is primarily impacted by the company's financial instability, as reflected in its fluctuating revenue and ongoing losses. Technical analysis shows mixed signals, with some positive momentum but overall downward trends. Valuation is a concern with a negative P/E ratio, indicating market skepticism about future profitability.
Positive Factors
Clinical Trials
The Phase I study of OV329 aims to provide more robust data for epilepsy trials, potentially boosting investor confidence in the stock.
Drug Development
OV329 shows significant advantages over Vigabatrin, such as efficacy at doses 1000 times lower, which may enhance the drug's market potential.
Financial Stability
Ovid Therapeutics is in a stable financial position with enough cash to fund operations into the second half of 2026, which is reassuring for investors.
Negative Factors
Drug Rights
Ovid does not regain rights to Soticlestat after Takeda's decision, affecting future revenue streams and stock valuation.
Partnerships
Takeda's discontinuation of Soticlestat development and Ovid not regaining rights to the drug negatively impacts revenue projections.
Stock Price Target
The 12-month price target for Ovid Therapeutics has been reduced from $2 to $1.50, indicating a less optimistic outlook.

Ovid Therapeutics (OVID) vs. SPDR S&P 500 ETF (SPY)

Ovid Therapeutics Business Overview & Revenue Model

Company DescriptionOvid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
How the Company Makes MoneyOvid Therapeutics makes money primarily through the development and commercialization of its pharmaceutical products aimed at rare neurological disorders. The company's revenue model includes income from the sale of approved drugs, licensing agreements, and collaborations with other pharmaceutical companies. Ovid may also receive milestone payments and royalties as part of partnerships with larger firms, where they co-develop or out-license their drug candidates. These strategic partnerships are significant as they provide additional funding and resources necessary for advancing their drug pipeline through clinical trials and towards market approval.

Ovid Therapeutics Financial Statement Overview

Summary
Ovid Therapeutics faces challenges with revenue consistency and profitability, showing significant fluctuations in income and ongoing losses. Despite low debt, declining equity and persistent cash flow deficits raise concerns about financial sustainability. Improvements in reducing net losses are positive, but overall financial health remains precarious.
Income Statement
40
Negative
Ovid Therapeutics has experienced significant revenue volatility, with a decline from $208M in 2021 to $566K in 2024, indicating unstable revenue generation. The gross profit margin is consistently low, and negative EBIT and net income margins indicate ongoing losses. Recent improvements in reducing losses are positive, but profitability remains a challenge.
Balance Sheet
55
Neutral
The company's debt-to-equity ratio is low, reflecting modest leverage, which is a positive indicator of financial stability. However, the declining stockholders' equity and total assets over recent years raise concerns about the company's ability to sustain its operations long-term. The equity ratio suggests a fair proportion of equity financing, but high liabilities relative to assets pose risks.
Cash Flow
50
Neutral
Operating cash flow remains negative, reflecting ongoing cash burn, although there has been a slight improvement in free cash flow in 2024. The company has relied on financing activities to support cash flow, which could indicate difficulties in generating sufficient cash from operations. Continued negative free cash flow is a concern for long-term sustainability.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue566.00K391.69K1.50M208.38M12.62M
Gross Profit566.00K-1.21M121.14K208.38M12.62M
EBITDA-61.27M-57.69M-54.17M124.40M-81.12M
Net Income-26.43M-52.34M-54.17M122.83M-81.04M
Balance Sheet
Total Assets92.17M144.03M155.27M194.54M75.93M
Cash, Cash Equivalents and Short-Term Investments53.08M105.83M129.00M187.80M72.03M
Total Debt14.76M16.00M16.54M0.000.00
Total Liabilities23.94M56.23M22.99M14.80M32.29M
Stockholders Equity68.23M87.80M132.27M179.75M43.63M
Cash Flow
Free Cash Flow-56.03M-45.92M-56.65M118.42M-51.97M
Operating Cash Flow-55.96M-45.78M-55.23M118.61M-51.58M
Investing Cash Flow54.59M-2.58M-87.88M-1.82M34.65M
Financing Cash Flow622.00K30.54M180.66K904.08K47.07M

Ovid Therapeutics Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.48
Price Trends
50DMA
0.32
Positive
100DMA
0.36
Positive
200DMA
0.67
Negative
Market Momentum
MACD
0.03
Negative
RSI
69.84
Neutral
STOCH
45.98
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OVID, the sentiment is Positive. The current price of 0.48 is above the 20-day moving average (MA) of 0.36, above the 50-day MA of 0.32, and below the 200-day MA of 0.67, indicating a neutral trend. The MACD of 0.03 indicates Negative momentum. The RSI at 69.84 is Neutral, neither overbought nor oversold. The STOCH value of 45.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OVID.

Ovid Therapeutics Risk Analysis

Ovid Therapeutics disclosed 64 risk factors in its most recent earnings report. Ovid Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Ovid Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (46)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
IPIPA
54
Neutral
$83.29M-121.65%-0.71%-169.29%
53
Neutral
$22.32M-93.19%6.96%32.32%
49
Neutral
$26.17M-36.31%15.73%51.00%
46
Neutral
C$197.02M-3.33-23.14%2.65%20.75%-0.36%
39
Underperform
$30.53M-134.15%95.48%
36
Underperform
$24.66M-39.78%84.17%
CVCVM
27
Underperform
$24.08M-238.64%30.96%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
OVID
Ovid Therapeutics
0.48
-0.48
-50.00%
CVM
Cel-Sci
4.17
-37.23
-89.93%
TENX
Tenax Therapeutics
5.88
2.56
77.11%
PULM
Pulmatrix
6.33
4.21
198.58%
IPA
ImmunoPrecise Antibodies
1.74
0.89
104.71%
CALC
CalciMedica
2.52
-1.65
-39.57%

Ovid Therapeutics Corporate Events

Executive/Board ChangesShareholder MeetingsStock Split
Ovid Therapeutics Approves Key Proposals at Annual Meeting
Neutral
Jul 10, 2025

On July 9, 2025, Ovid Therapeutics held its annual stockholders meeting, where several key proposals were voted on. Stockholders elected directors for a three-year term, approved executive compensation, ratified KPMG LLP as the accounting firm, and authorized a potential reverse stock split, indicating strategic financial adjustments.

The most recent analyst rating on (OVID) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Ovid Therapeutics stock, see the OVID Stock Forecast page.

Private Placements and FinancingBusiness Operations and Strategy
Ovid Therapeutics Sells Ganaxolone Royalties to Immedica
Neutral
Jun 25, 2025

On June 23, 2025, Ovid Therapeutics entered into an agreement with Immedica Pharma AB to sell its future royalties related to ganaxolone, a medicine used for treating CDKL5 deficiency disorder, for $7.0 million. This transaction provides Ovid with non-dilutive funding to support its operations, while Immedica gains control over ganaxolone’s intellectual property rights, enhancing its focus on rare diseases.

The most recent analyst rating on (OVID) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Ovid Therapeutics stock, see the OVID Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 18, 2025